Pharmacogenetics of opiates in clinical practice: The visible tip of the iceberg

Pharmacogenomics

Volumn 14, Issue 5, 2013, Pages 575-585

  Hajj, Aline ^a   Khabbaz, Lydia ^a   Laplanche, Jean Louis ^b,c   Peoc'h, Katell ^b,c  

^a SAINT JOSEPH UNIVERSITY   (Lebanon)

^b HÔPITAL LARIBOISIÈRE   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

association study; methadone; morphine; opiates; OPRM1; pharmacogenetic; polymorphisms

Indexed keywords

BUPRENORPHINE; CODEINE; DELTA OPIATE RECEPTOR; DIAMORPHINE; HYDROCODONE; KAPPA OPIATE RECEPTOR; METHADONE; MORPHINE; MU OPIATE RECEPTOR; NALOXONE; NALTREXONE; OPIATE; OXYCODONE; TRAMADOL;

ABCB1 GENE; ALCOHOLISM; ANALGESIA; ANALGESIC ACTIVITY; ARRB2 GENE; BINDING AFFINITY; CANCER PAIN; CHRONIC PAIN; CLINICAL PRACTICE; COMT GENE; CONFUSION; COUGHING; CYP2B6 GENE; CYP2D6 GENE; CYP3A4 GENE; DROWSINESS; DRUG ABSORPTION; DRUG BINDING SITE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG FATALITY; DRUG METABOLISM; DRUG OVERDOSE; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG STRUCTURE; FATIGUE; GENE; GENE DELETION; GENE FUNCTION; GENE IDENTIFICATION; GENETIC VARIABILITY; GENOTYPE; HALLUCINATION; HEART VENTRICLE FIBRILLATION; HUMAN; INSOMNIA; KCNJ6 GENE; LIBIDO DISORDER; NAUSEA; OPRM1 GENE; PAIN; PAIN ASSESSMENT; PHARMACODYNAMICS; PHARMACOGENETICS; POSTOPERATIVE PAIN; QT PROLONGATION; RESPIRATION DEPRESSION; REVIEW; SEDATION; SIDE EFFECT; SIGNAL TRANSDUCTION; TORSADE DES POINTES; UGT2B7 GENE; VOMITING;

ANALGESICS, OPIOID; GENETIC ASSOCIATION STUDIES; HUMANS; METHADONE; MORPHINE; OPIOID PEPTIDES; PAIN MANAGEMENT; PHARMACOGENETICS; RECEPTORS, OPIOID; RECEPTORS, OPIOID, MU;

EID: 84875943300     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.13.13     Document Type: Review

References (99)

1. Mague SD, Blendy JA. OPRM1 SNP (A118G): involvement in disease development, treatment response, and animal models. Drug Alcohol Depend. 108(3), 172-182 (2010
2. Kreek MJ, Bart G, Lilly C, LaForge KS, Nielsen DA. Pharmacogenetics and human molecular genetics of opiate and cocaine addictions and their treatments. Pharmacol. Rev. 57(1), 1-26 (2005 (Pubitemid 40283968)
3. Droney J, Riley J. Recent advances in the use of opioids for cancer pain. J. Pain Res. 2, 135-155 (2009
4. Wu CL, Raja SN. Treatment of acute postoperative pain. Lancet 377(9784), 2215-2225 (2011
5. Butler B, Rubin G, Lawrance A, Batey R, Bell J. Estimating the risk of fatal arrhythmia in patients in methadone maintenance treatment for heroin addiction. Drug Alcohol Rev. 30(2), 173-180 (2011
6. Angst MS, Phillips NG, Drover DR et al. Opioid pharmaco using a twin study paradigm: methods and procedures for determining familial aggregation and heritability. Twin Res. Hum. Genet. 13(5), 412-425 (2010
7. Matthes HW, Maldonado R, Simonin F et al. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene. Nature 383(6603), 819-823 (1996
8. Shabalina SA, Zaykin DV, Gris P et al. Expansion of the human mu-opioid receptor gene architecture: novel functional variants. Hum. Mol. Genet. 18(6), 1037-1051 (2009
9. Goodman L, Brunton LL, Chabner B, Knollmann BC. Goodman & Gilman's the Pharmacological Basis of Therapeutics (12th Edition). McGraw-Hill Medical, NY, USA (2012
10. Ravindranathan A, Joslyn G, Robertson M, Schuckit MA, Whistler JL, White RL. Functional characterization of human variants of the mu-opioid receptor gene. Proc. Natl Acad. Sci. USA 106(26), 10811-10816 (2009
11. Bond C, LaForge KS, Tian M et al. Single-nucleotide polymorphism in the human mu opioid receptor gene alters β-endorphin binding and activity: possible implications for opiate addiction. Proc. Natl Acad. Sci. USA 95(16), 9608-9613 (1998 (Pubitemid 28506279)
12. Zhang Y, Wang D, Johnson AD, Papp AC, Sadee W. Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G. J. Biol. Chem. 280(38), 32618-32624 (2005 (Pubitemid 41368304)
13. Niemi G, Breivik H. Epinephrine markedly improves thoracic epidural analgesia produced by a small-dose infusion of ropivacaine, fentanyl, and epinephrine after major thoracic or abdominal surgery: a randomized, double-blinded crossover study with and without epinephrine. Anesth. Analg. 94(6), 1598-1605 (2002 (Pubitemid 34556653)
14. Raja SN, Choi Y, Asano Y, Holmes C, Goldstein DS. Arteriovenous differences in plasma concentrations of catechols in rats with neuropathic pain. Anesthesiology 83(5), 1000-1008 (1995
15. Rakvag TT, Klepstad P, Baar C et al. The Val158Met polymorphism of the human catechol-O-methyltransferase (COMT) gene may influence morphine requirements in cancer pain patients. Pain 116(1-2), 73-78 (2005
16. Lachman HM, Papolos DF, Saito T, Yu YM, Szumlanski CL, Weinshilboum RM. Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics 6(3), 243-250 (1996 (Pubitemid 26226317)
17. Oneda B, Crettol S, Bochud M et al. β-arrestin2 influences the response to methadone in opioid-dependent patients. Pharmacogenomics J. 11(4), 258-266 (2011
18. Klein U, Muller C, Chu P, Birnbaumer M, von Zastrow M. Heterologous inhibition of G protein-coupled receptor endocytosis mediated by receptor-specific trafficking of β-arrestins. J. Biol. Chem. 276(20), 17442-17447 (2001
19. Kang M, Maguma HT, Smith TH, Ross GR, Dewey WL, Akbarali HI. The role of β-arrestin2 in the mechanism of morphine tolerance in the mouse and guinea pig gastrointestinal tract. J. Pharmacol. Exp. Ther. 340(3), 567-576 (2012
20. Lotsch J, Pruss H, Veh RW, Doehring A. A KCNJ6 (Kir3.2, GIRK2) gene polymorphism modulates opioid effects on analgesia and addiction but not on pupil size. Pharmacogenet. Genomics 20(5), 291-297 (2010
21. Bouer R, Barthe L, Philibert C, Tournaire C, Woodley J, Houin G. The roles of P-glycoprotein and intracellular metabolism in the intestinal absorption of methadone: in vitro studies using the rat everted intestinal sac. Fundam. Clin. Pharmacol. 13(4), 494-500 (1999 (Pubitemid 32250275)
22. Mashayekhi SO, Sattari MR, Routledge PA. Evidence of active transport involvement in morphine transport via MDCKII and MDCKPGP cell lines. Res. Pharm. Sci. 5(2), 99-106 (2010
23. Tournier N, Chevillard L, Megarbane B, Pirnay S, Scherrmann JM, Decleves X. Interaction of drugs of abuse and maintenance treatments with human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2). Int. J. Neuropsychopharmacol. 13(7), 905-915 (2010
24. Wandel C, Kim R, Wood M, Wood A. Interaction of morphine, fentanyl, sufentanil, alfentanil, and loperamide with the efflux drug transporter P-glycoprotein. Anesthesiology 96(4), 913-920 (2002 (Pubitemid 34266685)
25. Hoffmeyer S, Burk O, von Richter O et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl Acad. Sci. USA 97(7), 3473-3478 (2000 (Pubitemid 30183327)
26. Wang D, Johnson AD, Papp AC, Kroetz DL, Sadee W. Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenet. Genomics 15(10), 693-704 (2005 (Pubitemid 41345321)
27. Osborne R, Joel S, Trew D, Slevin M. Analgesic activity of morphine-6-glucuronide. Lancet 1(8589), 828 (1988 (Pubitemid 18094944)
28. Smith MT. Neuroexcitatory effects of morphine and hydromorphone: evidence implicating the 3-glucuronide metabolites. Clin. Exp. Pharmacol. Physiol. 27(7), 524-528 (2000 (Pubitemid 30417999)
29. Eichelbaum M, Evert B. Influence of pharmacogenetics on drug disposition and response. Clin. Exp. Pharmacol. Physiol. 23(10-11), 983-985 (1996 (Pubitemid 26361726)
30. Lamba JK, Lin YS, Schuetz EG, Thummel KE. Genetic contribution to variable human CYP3A-mediated metabolism. Adv. Drug Deliv. Rev. (2012
31. Totah RA, Sheffels P, Roberts T, Whittington D, Thummel K, Kharasch ED. Role of CYP2B6 in stereoselective human methadone metabolism. Anesthesiology 108(3), 363-374 (2008 (Pubitemid 351304229)
32. Walter C, Lotsch J. Meta-analysis of the relevance of the OPRM1 118A>G genetic variant for pain treatment. Pain 146(3), 270-275 (2009
33. Finco G, Pintor M, Sanna D et al. Is target opioid therapy within sight? Minerva Anestesiol. 78(4), 462-472 (2012
34. Tammimaki A, Mannisto PT. Catechol-O-methyltransferase gene polymorphism and chronic human pain: a systematic review and meta-analysis. Pharmacogenet. Genomics 22(9), 673-691 (2012
35. Reyes-Gibby CC, Shete S, Rakvag T et al. Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT gene. Pain 130(1-2), 25-30 (2007 (Pubitemid 46850782)
36. Rakvag TT, Ross JR, Sato H, Skorpen F, Kaasa S, Klepstad P. Genetic variation in the catechol-O-methyltransferase (COMT) gene and morphine requirements in cancer patients with pain. Mol. Pain 4, 64 (2008
37. Zubieta JK, Heitzeg MM, Smith YR et al. COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor. Science 299(5610), 1240-1243 (2003 (Pubitemid 36237467)
38. Ross JR, Riley J, Taegetmeyer AB et al. Genetic variation and response to morphine in cancer patients: catechol-O-methyltransferase and multidrug resistance1 gene polymorphisms are associated with central side effects. Cancer 112(6), 1390-1403 (2008 (Pubitemid 351429755)
39. Kim H, Mittal DP, Iadarola MJ, Dionne RA. Genetic predictors for acute experimental cold and heat pain sensitivity in humans. J. Med. Genet. 43(8), e40 (2006
40. Campa D, Gioia A, Tomei A, Poli P, Barale R. Association of ABCB1/MDR1 and OPRM1 gene polymorphisms with morphine pain relief. Clin. Pharmacol. Ther. 83(4), 559-566 (2008 (Pubitemid 351417058)
41. Meineke I, Freudenthaler S, Hofmann U et al. Pharmacokinetic modelling of morphine, morphine-3-glucuronide and morphine-6-glucuronide in plasma and cerebrospinal fluid of neurosurgical patients after short-term infusion of morphine. Br. J. Clin. Pharmacol. 54(6), 592-603 (2002 (Pubitemid 36002586)
42. Lotsch J, von Hentig N, Freynhagen R et al. Cross-sectional analysis of the influence of currently known pharmacogenetic modulators on opioid therapy in outpatient pain centers. Pharmacogenet. Genomics 19(6), 429-436 (2009
43. Klepstad P, Fladvad T, Skorpen F et al. Influence from genetic variability on opioid use for cancer pain: a European genetic association study of 2294 cancer pain patients. Pain 152(5), 1139-1145 (2011
44. Sawyer MB, Innocenti F, Das S et al. A pharmacogenetic study of uridine diphosphate-glucuronosyltransferase 2B7 in patients receiving morphine. Clin. Pharmacol. Ther. 73(6), 566-574 (2003 (Pubitemid 37249128)
45. Holthe M, Klepstad P, Zahlsen K et al. Morphine glucuronide-to-morphine plasma ratios are unaffected by the UGT2B7 H268Y and UGT1A1*28 polymorphisms in cancer patients on chronic morphine therapy. Eur. J. Clin. Pharmacol. 58(5), 353-356 (2002 (Pubitemid 34983926)
46. Coulbault L, Beaussier M, Verstuyft C et al. Environmental and genetic factors associated with morphine response in the postoperative period. Clin. Pharmacol. Ther. 79(4), 316-324 (2006
47. Holthe M, Rakvag TN, Klepstad P et al. Sequence variations in the UDP-glucuronosyltransferase 2B7 (UGT2B7) gene: identification of 10 novel single nucleotide polymorphisms (SNPs) and analysis of their relevance to morphine glucuronidation in cancer patients. Pharmacogenomics J. 3(1), 17-26 (2003 (Pubitemid 36432463)
48. Darbari DS, van Schaik RH, Capparelli EV, Rana S, McCarter R, van den Anker J. UGT2B7 promoter variant -840G>A contributes to the variability in hepatic clearance of morphine in patients with sickle cell disease. Am. J. Hematol. 83(3), 200-202 (2008 (Pubitemid 351303943)
49. Nishizawa D, Nagashima M, Katoh R et al. Association between KCNJ6 (GIRK2) gene polymorphisms and postoperative analgesic requirements after major abdominal surgery. PLoS ONE 4(9), e7060 (2009
50. Henker RA, Lewis A, Dai F et al. The associations between OPRM1 and COMT genotypes and postoperative pain, opioid use, and opioid-induced sedation. Biol. Res. Nurs. doi:10.1177/1099800411436171 (2012) (Epub ahead of print
51. Ross JR, Rutter D, Welsh K et al. Clinical response to morphine in cancer patients and genetic variation in candidate genes. Pharmacogenomics J. 5(5), 324-336 (2005 (Pubitemid 41486231)
52. Laugsand EA, Fladvad T, Skorpen F et al. Clinical and genetic factors associated with nausea and vomiting in cancer patients receiving opioids. Eur. J. Cancer 47(11), 1682-1691 (2011
53. Fujita K, Ando Y, Yamamoto W et al. Association of UGT2B7 and ABCB1 genotypes with morphine-induced adverse drug reactions in Japanese patients with cancer. Cancer Chemother. Pharmacol. 65(2), 251-258 (2011
54. Romberg RR, Olofsen E, Bijl H et al. Polymorphism of mu-opioid receptor gene (OPRM1:c.118A>G) does not protect against opioid-induced respiratory depression despite reduced analgesic response. Anesthesiology 102(3), 522-530 (2005 (Pubitemid 40315140)
55. Eap CB, Buclin T, Baumann P. Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clin. Pharmacokinet. 41(14), 1153-1193 (2002 (Pubitemid 35398691)
56. Crettol S, Deglon JJ, Besson J et al. ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment. Clin. Pharmacol. Ther. 80(6), 668-681 (2006 (Pubitemid 44920225)
57. Eap CB, Crettol S, Rougier JS et al. Stereoselective block of hERG channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metabolizers. Clin. Pharmacol. Ther. 81(5), 719-728 (2007 (Pubitemid 46625109)
58. Elkader AK, Brands B, Dunn E, Selby P, Sproule BA. Major depressive disorder and patient satisfaction in relation to methadone pharmacokinetics and pharmacodynamics in stabilized methadone maintenance patients. J. Clin. Psychopharmacol. 29(1), 77-81 (2009
59. Lotsch J, Skarke C, Wieting J et al. Modulation of the central nervous effects of levomethadone by genetic polymorphisms potentially affecting its metabolism, distribution, and drug action. Clin. Pharmacol. Ther. 79(1), 72-89 (2006 (Pubitemid 43069580)
60. Oneda B, Crettol S, Jaquenoud Sirot E, Bochud M, Ansermot N, Eap CB. The P450 oxidoreductase genotype is associated with CYP3A activity in vivo as measured by the midazolam phenotyping test. Pharmacogenet. Genomics 19(11), 877-883 (2009
61. Coller JK, Barratt DT, Dahlen K, Loennechen MH, Somogyi AA. ABCB1 genetic variability and methadone dosage requirements in opioid-dependent individuals. Clin. Pharmacol. Ther. 80(6), 682-690 (2006 (Pubitemid 44920224)
62. Levran O, O'Hara K, Peles E et al. ABCB1 (MDR1) genetic variants are associated with methadone doses required for effective treatment of heroin dependence. Hum. Mol. Genet. 17(14), 2219-2227 (2008 (Pubitemid 351916578)
63. Iribarne C, Berthou F, Baird S et al. Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes. Chem. Res. Toxicol. 9(2), 365-373 (1996 (Pubitemid 26079977)
64. Eap CB, Broly F, Mino A et al. Cytochrome P450 2D6 genotype and methadone steady-state concentrations. J. Clin. Psychopharmacol. 21(2), 229-234 (2001 (Pubitemid 32221062)
65. Gerber JG, Rhodes RJ, Gal J. Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19. Chirality 16(1), 36-44 (2004 (Pubitemid 37532283)
66. Crettol S, Deglon JJ, Besson J et al. Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment. Clin. Pharmacol. Ther. 78(6), 593-604 (2005 (Pubitemid 41773635)
67. Fonseca F, de la Torre R, Diaz L et al. Contribution of cytochrome P450 and ABCB1 genetic variability on methadone pharmacokinetics, dose requirements, and response. PLoS ONE 6(5), e19527 (2011
68. Levran O, Peles E, Hamon S, Randesi M, Adelson M, Kreek MJ. CYP2B6 SNPs are associated with methadone dose required for effective treatment of opioid addiction. Addict. Biol. doi:10.1111/j.1369-1600.2011.00349.x (2011) (Epub ahead of print
69. De Bels D, Staroukine M, Devriendt J. Torsades de pointes due to methadone. Ann. Intern. Med. 139(2), e156 (2003
70. Lin C, Somberg T, Molnar J, Somberg J. The effects of chiral isolates of methadone on the cardiac potassium channel IKr. Cardiology 113(1), 59-65 (2009
71. Wang SC, Tsou HH, Chen CH et al. Genetic polymorphisms in the opioid receptor mu1 gene are associated with changes in libido and insomnia in methadone maintenance patients. Eur. Neuropsychopharmacol. 22(10), 695-703 (2012
72. Mignat C, Wille U, Ziegler A. Affinity profiles of morphine, codeine, dihydrocodeine and their glucuronides at opioid receptor subtypes. Life Sci. 56(10), 793-799 (1995
73. Volpe DA, McMahon Tobin GA, Mellon RD et al. Uniform assessment and ranking of opioid mu receptor binding constants for selected opioid drugs. Regul. Toxicol. Pharmacol. 59(3), 385-390 (2011
74. Crews KR, Gaedigk A, Dunnenberger HM et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. Clin. Pharmacol. Ther. 91(2), 321-326 (2012
75. Koren G, Cairns J, Chitayat D, Gaedigk A, Leeder SJ. Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet 368(9536), 704 (2006 (Pubitemid 44223697)
76. Madadi P, Ross CJ, Hayden MR et al. Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case-control study. Clin. Pharmacol. Ther. 85(1), 31-35 (2009
77. Levo A, Koski A, Ojanpera I, Vuori E, Sajantila A. Post-mortem SNP analysis of CYP2D6 gene reveals correlation between genotype and opioid drug (tramadol) metabolite ratios in blood. Forensic Sci. Int. 135(1), 9-15 (2003 (Pubitemid 36957845)
78. Stamer UM, Stuber F, Muders T, Musshoff F. Respiratory depression with tramadol in a patient with renal impairment and CYP2D6 gene duplication. Anesth. Analg. 107(3), 926-929 (2008
79. Coluzzi F, Mattia C. Oxycodone. Pharmacological profile and clinical data in chronic pain management. Minerva Anestesiol. 71(7-8), 451-460 (2005 (Pubitemid 43932971)
80. Lalovic B, Kharasch E, Hoffer C, Risler L, Liu-Chen LY, Shen DD. Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites. Clin. Pharmacol. Ther. 79(5), 461-479 (2006
81. Kalso E. How different is oxycodone from morphine? Pain 132(3), 227-228 (2007 (Pubitemid 350051575)
82. Andreassen TN, Eftedal I, Klepstad P et al. Do CYP2D6 genotypes reflect oxycodone requirements for cancer patients treated for cancer pain? A cross-sectional multicentre study. Eur. J. Clin. Pharmacol. 68(1), 55-64 (2012
83. Samer CF, Daali Y, Wagner M et al. Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety. Br. J. Pharmacol. 160(4), 919-930 (2010
84. Jannetto PJ, Wong SH, Gock SB, Laleli-Sahin E, Schur BC, Jentzen JM. Pharmaco as molecular autopsy for postmortem forensic toxicology: genotyping cytochrome P450 2D6 for oxycodone cases. J. Anal. Toxicol. 26(7), 438-447 (2002 (Pubitemid 36206778)
85. Madadi P, Hildebrandt D, Gong IY et al. Fatal hydrocodone overdose in a child: pharmacogenetics and drug interactions. Pediatrics 126(4), e986-e989 (2010
86. Anton RF, Oroszi G, O'Malley S et al. An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch. Gen. Psychiatry 65(2), 135-144 (2008 (Pubitemid 351222547)
87. Kim SG, Kim CM, Choi SW et al. A micro opioid receptor gene polymorphism (A118G) and naltrexone treatment response in adherent Korean alcohol-dependent patients. Psychopharmacology (Berl.) 201(4), 611-618 (2009
88. Oslin DW, Berrettini W, Kranzler HR et al. A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology 28(8), 1546-1552 (2003 (Pubitemid 41070891)
89. Ray LA, Courtney KE, Bujarski S, Squeglia LM. Pharmacogenetics of alcoholism: a clinical neuroscience perspective. Pharmacogenomics 13(2), 129-132 (2012
90. Lotsch J, Geisslinger G. Pharmacogenetics of new analgesics. Br. J. Pharmacol. 163(3), 447-460 (2011
91. Klepstad P, Rakvag TT, Kaasa S et al. The 118 A > G polymorphism in the human mu-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease. Acta Anaesthesiol. Scand. 48(10), 1232-1239 (2004
92. Chou WY, Yang LC, Lu HF et al. Association of mu-opioid receptor gene polymorphism (A118G) with variations in morphine consumption for analgesia after total knee arthroplasty. Acta Anaesthesiol. Scand. 50(7), 787-792 (2006
93. Sia AT, Lim Y, Lim EC et al. A118G single nucleotide polymorphism of human mu-opioid receptor gene influences pain perception and patient-controlled intravenous morphine consumption after intrathecal morphine for postcesarean analgesia. Anesthesiology 109(3), 520-526 (2008
94. Hayashida M, Nagashima M, Satoh Y et al. Analgesic requirements after major abdominal surgery are associated with OPRM1 gene polymorphism genotype and haplotype. Pharmacogenomics 9(11), 1605-1616 (2008
95. Huehne K, Leis S, Muenster T et al. High post surgical opioid requirements in Crohn's disease are not due to a general change in pain sensitivity. Eur. J. Pain 13(10), 1036-1042 (2009
96. Kolesnikov Y, Gabovits B, Levin A, Voiko E, Veske A. Combined catechol-O-methyltransferase and mu-opioid receptor gene polymorphisms affect morphine postoperative analgesia and central side effects. Anesth. Analg. 112(2), 448-453 (2011
97. Shinderman M, Maxwell S, Brawand-Amey M, Golay KP, Baumann P, Eap CB. Cytochrome P4503A4 metabolic activity, methadone blood concentrations, and methadone doses. Drug Alcohol Depend. 69(2), 205-211 (2003 (Pubitemid 36259782)
98. Lotsch J, Geisslinger G. Relevance of frequent mu-opioid receptor polymorphisms for opioid activity in healthy volunteers. Pharmacogenomics J. 6(3), 200-210 (2006 (Pubitemid 43820870)
99. Wang SC, Ho IK, Tsou HH et al. CYP2B6 polymorphisms influence the plasma concentration and clearance of the methadone Senantiomer. J. Clin. Psychopharmacol. 31(4), 463-469 (2011